Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aviral Singh

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 15, 2020
Prognostic Value of <sup>18</sup>F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide TherapyJingjing Zhang, Qingxing Liu, Aviral Singh, et al.
Frontiers in Endocrinology|July 9, 2025
The PANEN nomogram: clinical decision support for patients with metastatic pancreatic neuroendocrine neoplasm referred for peptide receptor radionuclide therapyAviral Singh, Sebastian Sanduleanu, Harshad R Kulkarni, et al.
Scientific Reports|May 19, 2026
Metaheuristic-optimized bell-shaped slotted pentaband patch antenna for C, X, Ku, and K band applicationsMohammad Hannan, Aviral Singh, Shivam Bansal, et al.
Nuclear Medicine and Molecular Imaging|June 7, 2021
The Outcome and Safety of Re-challenge Lutetium-177 PSMA (<sup>177</sup>Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer-a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case ReportMasha Maharaj, Lucille Heslop, Trisha Govender, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 18, 2018
Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 PatientsJingjing Zhang, Harshad R Kulkarni, Aviral Singh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 27, 2019
Clinical Outcomes of <sup>177</sup>Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane ChemotherapyThomas W Barber, Aviral Singh, Harshad R Kulkarni, et al.
Nuclear Medicine Communications|December 21, 2007
Clinical significance of myocardial perfusion abnormalities in patients with varying degree of coronary artery stenosisNigora Rasulova, Aviral Singh, Ourania Demetriadou, et al.
Nuclear Medicine and Molecular Imaging|February 3, 2018
Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: an Empirical Proof of a Promising ConceptRichard P Baum, Thomas Langbein, Aviral Singh, et al.
Scientific Reports|January 21, 2025
MythicVision: a deep learning powered mobile application for understanding Indian mythological deities using weight centric decision approachTauseef Khan, Aditya Nitin Patil, Aviral Singh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 10, 2019
<sup>177</sup>Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning KidneyJingjing Zhang, Harshad R Kulkarni, Aviral Singh, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 15, 2020
Prognostic Value of <sup>18</sup>F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide TherapyJingjing Zhang, Qingxing Liu, Aviral Singh, et al.
Frontiers in Endocrinology|July 9, 2025
The PANEN nomogram: clinical decision support for patients with metastatic pancreatic neuroendocrine neoplasm referred for peptide receptor radionuclide therapyAviral Singh, Sebastian Sanduleanu, Harshad R Kulkarni, et al.
Scientific Reports|May 19, 2026
Metaheuristic-optimized bell-shaped slotted pentaband patch antenna for C, X, Ku, and K band applicationsMohammad Hannan, Aviral Singh, Shivam Bansal, et al.
Nuclear Medicine and Molecular Imaging|June 7, 2021
The Outcome and Safety of Re-challenge Lutetium-177 PSMA (<sup>177</sup>Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer-a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case ReportMasha Maharaj, Lucille Heslop, Trisha Govender, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 18, 2018
Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 PatientsJingjing Zhang, Harshad R Kulkarni, Aviral Singh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 27, 2019
Clinical Outcomes of <sup>177</sup>Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane ChemotherapyThomas W Barber, Aviral Singh, Harshad R Kulkarni, et al.
Nuclear Medicine Communications|December 21, 2007
Clinical significance of myocardial perfusion abnormalities in patients with varying degree of coronary artery stenosisNigora Rasulova, Aviral Singh, Ourania Demetriadou, et al.
Nuclear Medicine and Molecular Imaging|February 3, 2018
Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: an Empirical Proof of a Promising ConceptRichard P Baum, Thomas Langbein, Aviral Singh, et al.
Scientific Reports|January 21, 2025
MythicVision: a deep learning powered mobile application for understanding Indian mythological deities using weight centric decision approachTauseef Khan, Aditya Nitin Patil, Aviral Singh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 10, 2019
<sup>177</sup>Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning KidneyJingjing Zhang, Harshad R Kulkarni, Aviral Singh, et al.
Pageof 6